We are proud to announce the return of the 11th annual ADMET conference 2016 in London!
ADME and toxicology testing are one of the most important research activities related to new drug discovery. Ensuring a good
ADMET study will accelerate approval and therefore commercialization of your drug product - and hence pharmacokinetics remain at the forefront of drug formulation and development.
Since the pharmaceutical and biotechnology companies are utilising innovative technologies,
ADME and toxicology screening at early stages of drug discovery and development process has become even more imperative.
Join us at our 11th annual
ADMET taking place on the 13th - 14th June 2016 in London. This event will explore novel and emerging non- clinical
ADME approaches, structure based prediction of
ADME properties, PK/PD modeling to validate drug targets and toxicity and many more.
Benefits of Attending
A series of practical case studies, interactive roundtables and panel discussion facilitated by leading industry experts will provide executives with useful tools and best practices to:
- Optimise human ADMET studies to assess clinically-relevant drug bioavailability
- Use a population pharmacokinetic approach to assess DDI
- Evaluate drug design interaction
- Predict drug design interaction
- Review the structure based prediction of ADME properties
- Learn about In-Vivo drug-drug interaction
- Gain insight into PK/PD modeling to validate drug targets and toxicity
Plus An Interactive Half-Day Post-Conference Workshop | Wednesday 15th June 2016
Molecular properties and intermolecular interactions in virtual ADMET assessmentLed by Mire Zloh, Head of Medicinal and Analytical Chemistry Research Group, University of Hertfordshire
and Teresa Barata, Research Associate, UCL School of Pharmacy
8:30 - 12:30
Speakers
- Armin Sepp, Manager, GSK
- Carl Petersson, DMPK NCE Senior Designer, Merck Serono
- Friedemann Schmidt, Senior Scientist, Preclinical Safety, Sanofi-Aventis
- Hans Westerhoff, Professor of Microbial Physiology, University of Manchester
- Ian Wilson, Chair, Drug Metabolism and Molecular Toxicology, Imperial College
- John Dearden, Emeritus Professor, Liverpool John Moores University
- Karelle Menochet, Principal Scientist, UCB
- Ken Page, Principal Scientist, RedX Immunology Ltd
- Kunal Taskar, Investigator, MET DMPK, RD Platform Technology , GSK
- Laurent Salphati, Senior Scientist, Drug Metabolism and Pharmacokinetics, Genentech
- Lena Gustavsson, Head of Section Drug-Drug Interactions , Lundbeck Limited
- Mark Wenlock, Director, Insilicolynx
- Mire Zloh, Head of Pharmaceutical Chemistry , University of Hertfordshire
- Na Li, Senior Staff Scientist, Corning, Inc
- Nick Plant, Reader in Molecular Toxicology, University Of Surrey
- Pau Aceves, Senior Clinical Pharmacologist, Takeda UK Ltd
- Peter Littlewood, Director DMPK, Vertex Pharmaceuticals
- Thierry Lave, Head Project Leaders/Modelling & Simulation, Roche Innovation Center Basel
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right isde of the page.
Venue
Holiday Inn Kensington Forum
97 Cromwell Rd, Kensington, SW7 4DN
London, UK
Who should attend
- DMPK
- Computational
- Principle scientist
- Drug metabolism
- ADME Toxicologist
- Research fellow
- Computational scientist
- PK/PD modeling
- Toxicologist
- Anatomy
- Stem cell
Venue
Holiday Inn Kensington Forum97 Cromwell Road
London, United Kingdom
